Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases afflicting the Chinese population. The company announced today that its newly acquired subsidiary, Shaanxi Weinan, signed a … Continue reading →

Through a full suite of investor relations services, MissionIR is able to custom tailor the most effective communication strategy for its clients. By utilizing a comprehensive database, MissionIR strategically matches those clients with brokers, hedge funds, money managers, professional traders, … Continue reading →

Noble Financial Capital Markets will be presenting its eighth annual BOCEMb equity conference at the Hard Rock Hotel & Casino in Hollywood (Ft. Lauderdale), Florida, January 17-18, 2012. The conference will feature approximately 140 public companies, as well as a … Continue reading →

Leading molecular diagnostics company, Vermillion, Inc., announced today that it has completed purchasing almost all of the assets associated with Correlogic Systems, Inc., the ovarian cancer diagnostics business. Before filing for bankruptcy protection under Chapter 11 in 2010, Correlogic pioneered … Continue reading →

Today, private company BI-LO, LLC, operator of some 207 supermarkets and 116 in-store pharmacies in the US SE market, and Winn-Dixie Stores, Inc. (WINN), with their fleet of some 480 supermarkets/380 in-store pharmacies, announced a merger, resulting in an extremely … Continue reading →

Genetic Technologies Ltd., a leading-edge genetic testing and fertility services business from Australia that has an extensive range of international patents and allied research activities aimed at uncovering the impact of DNA on health, recently announced the appointment of Dr. … Continue reading →

Noble Financial Capital Markets, with offices around the country, defines itself as a full-service investment banking boutique, focused on private, micro-cap and small-cap emerging growth companies, with a special emphasis on Healthcare and Technology sectors. The company is known for … Continue reading →

Biopharmaceutical company Chelsea Therapeutics International Ltd. today announced it has received allowance from the U.S. Patent & Trademark Office (USPTO) for its patent application “Threo-DOPS Controlled Release Formulation.” This marks the second major milestone for the company’s intellectual patent portfolio … Continue reading →